Evidence map›Paper›PMID 39005129›Full record

ReviewMicroRNA (Shariqah, United Arab Emirates)2024

The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.

Ramin Raoufinia, Parisa Afrasiabi, Amir Dehghanpour, Sara Memarpour, Sayyed Hadi Sayyed Hosseinian, Ehsan Saburi, Karim Naghipoor, Samaneh Rezaei, Meisam Haghmoradi, Neda Keyhanvar and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in MicroRNA (Shariqah, United Arab Emirates), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ramin RaoufiniaNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.ORCID 0000-0002-6162-8446
Parisa AfrasiabiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Amir DehghanpourFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Sara MemarpourMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sayyed Hadi Sayyed HosseinianOrthopedic Research Center, Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Ehsan SaburiMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Karim NaghipoorMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Samaneh RezaeiVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Meisam HaghmoradiOrthopedic Research Center, Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Neda KeyhanvarDepartment of Biochemistry & Biophysics, University of California San Francisco, San Francisco, CA, 94107, USA.
Mehdi RostamiDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Farhad FakoorDepartment of Paramedical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Mohammadali Izadpanah KazemiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Meysam MoghbeliMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid Reza RahimiMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID 0000-0002-2269-4109

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer, the second greatest cause of mortality worldwide, frequently causes bone metastases in patients with advanced-stage carcinomas such as prostate, breast, and lung cancer. The existence of these metastases contributes to the occurrence of skeletal-related events (SREs), which are defined by excessive pain, pathological fractures, hypercalcemia, and spinal cord compression. These injurious incidents leave uncomfortably in each of the cancer patient's life quality. Primary bone cancers, including osteosarcoma (OS), chondrosarcoma (CS), and Ewing's sarcoma (ES), have unclear origins. MicroRNA (miRNA) expression patterns have been changed in primary bone cancers such as OS, CS, and ES, indicating a role in tumor development, invasion, metastasis, and treatment response. These miRNAs are persistent in circulation and exhibit distinct patterns in many forms of bone tumors, making them potential biomarkers for early detection and treatment of such diseases. Given their crucial regulatory functions in various biological processes and conditions, including cancer, this study aims to look at miRNAs' activities and possible contributions to bone malignancies, focusing on OS, CS, and ES. In conclusion, miRNAs are valuable tools for diagnosing, monitoring, and predicting OS, CS, and ES outcomes. Further research is required to fully comprehend the intricate involvement of miRNAs in these bone cancers and to develop effective miRNA-based treatments.

Indexed as

Biomarkers, TumorBone NeoplasmsMicroRNAsChondrosarcomaGene Expression Regulation, NeoplasticHumansOsteosarcomaSarcoma, EwingBiomarkers, TumorMicroRNAsbone metastases.chondrosarcomaewing's sarcomaMicroRNAosteosarcomatumor cells

Identifiers

PMID39005129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.